For research use only. Not for therapeutic Use.
FLT3-IN-16（Cat No.:I042913）is a small molecule inhibitor targeting the FLT3 receptor, a tyrosine kinase involved in the regulation of hematopoiesis and immune cell differentiation. Mutations in FLT3, particularly the FLT3-ITD mutation, are commonly found in acute myeloid leukemia (AML) and contribute to uncontrolled cell proliferation. By inhibiting FLT3 activity, FLT3-IN-16 aims to prevent leukemia cell growth and improve patient outcomes. It is being studied in preclinical and clinical settings as a potential treatment for AML, particularly in cases with FLT3 mutations, offering a targeted approach for more effective cancer therapy.
| CAS Number | 298207-49-5 |
| Synonyms | N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)pyridine-3-carboxamide |
| Molecular Formula | C15H15N3O2S |
| Purity | ≥95% |
| IUPAC Name | N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)pyridine-3-carboxamide |
| InChI | InChI=1S/C15H15N3O2S/c16-13(19)12-10-5-1-2-6-11(10)21-15(12)18-14(20)9-4-3-7-17-8-9/h3-4,7-8H,1-2,5-6H2,(H2,16,19)(H,18,20) |
| InChIKey | VPZYTLSYUXWBNC-UHFFFAOYSA-N |
| SMILES | C1CCC2=C(C1)C(=C(S2)NC(=O)C3=CN=CC=C3)C(=O)N |
